Positions

Associate Professor of Medicine in the School of Medicine

2024 School of Medicine

Member of the Duke Cancer Institute in the School of Medicine

2016 School of Medicine

Education

M.D., Duke University, School of Medicine 2007

2007 Duke University, School of Medicine

Resident, Duke University, School of Medicine, INTERNAL MEDICINE 2007 - 2010

2010 Duke University, School of Medicine

Clinical Trials

Catapult: Ph1a/b CAP-100 (Chronic Lymphocytic Leukemia)

S1925: Phase III Study of Newly Diagnosed Asymptomatic High-Risk Patents with CLL/SLL

BeiGene: Long-term Extension Study of Zanubrutinib in Patients with B-Cell Malignancies

Nurix Phase 1 dose escalation, expansion evaluating NX-5948 (Leukemia and Lymphoma)

Juno (Lymphoma)

CarnaBioC1763102:Oral AS-1763 in Previous Treated Lymphoma or Non-Hodgkin Lymphoma

Load More

Publications, Grants & Awards

• Grants (34)
• Academics Articles (73)

Showing 1 - 5 of 34

A Phase 1b Study of Oral AS-1763 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

2025-2030Carna Biosciences, Inc.

A Phase 1 Study of ABBV-453 in Adult Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

2025-2030AbbVie Inc.

Short Title Phase 3 Sonrotoclax + Zanubrutinib compared with Ven + Obinutuzumab in Patients untreated CLL

2024-2029BeiGene USA, Inc.

A Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Bruton?s Tyrosine Kinase (BTK) Degrader, in Adults with Relapsed/Refractory B-cell Malignancies

2024-2029Nurix Therapeutics, Inc.

An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients with B-cell Malignancies

2023-2028BeiGene USA, Inc.

Offices & Contact

2400 Pratt St Suite 5000
Durham, NC
27710

DUMC Box 3961
Durham, NC
27710